Related Experiment Video For Biotransformation
Updated: May 11, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Inter-species variability in 4,4'-methylenedianiline metabolism: insights from human and rat precision-cut
Marieke A J Hof1, Jeffrey Sewdihal2, Stepan Stepanovic3
1Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.
Abstract:
Occupational exposure to 4,4'-methylenedianiline (MDA), a precursor in polyurethane foam production, has been linked to liver disease and cancer. Most evidence, however, comes from underpowered epidemiological studies, while empirical data are mainly from animal models, which point toward liver metabolism generating reactive metabolites. We thus used precision-cut liver slices (PCLS) from human and rat donors which we exposed to MDA at 10 and 100 μM for 24 h, and supernatants were analyzed by liquid chromatography-'SWATH' mass spectrometry. The major metabolite detected in hPCLS and rPCLS was MDA's known N-acetyl derivative, comprising approximately 80-90 % of metabolites at 10 μM and 50-60 % at 100 μM. Other metabolites were phase II conjugates, including putative N-formylation and urea-glutamine and urea-ethanolamine adducts. The latter accounted for ∼10 % of metabolites at 10 μM, increasing to 50 % at 100 μM in rPCLS but only reaching ∼25 % in hPCLS. Cell viability remained at 100 % across all human conditions and in rPCLS at 10 μM, but it dropped below 5 % at 100 μM. In conclusion, this study confirmed MDA's well-known N-acetyl metabolite across both species, while also unveiling rather unusual, previously unreported conjugates. Additionally, distinct interspecies differences were observed, underscoring the need for human-based studies.
More Related Videos
Related Concept Videos
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

